Rania B.
- Country
- France
- Department
- Oncologie
Research Overview
- Phase 3 Randomized, Double-Blind Study of Niraparib, Abiraterone Acetate, and Prednisone in HRR Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer
- Phase 3 Randomized Study of Zanidatamab with Chemotherapy ± Tislelizumab vs. Trastuzumab with Chemotherapy in HER2-Positive Advanced Gastroesophageal Adenocarcinoma
- Efficacy and Safety of Pembrolizumab with Chemoradiotherapy versus Chemoradiotherapy Alone in Muscle-Invasive Bladder Cancer: A Phase III Randomized Trial
Data & Insights
Has run more than one trial at 16 of 120 partner sites.
Specializations
Gastrointestinal Oncology
This investigator specializes in treating advanced gastroesophageal adenocarcinoma (GEA), with particular focus on HER2-positive gastric and esophageal cancers. Their research explores innovative therapeutic combinations for patients with unresectable or metastatic disease.
- HER2-targeted therapies
- Combination immunotherapy approaches
- Advanced gastric cancer treatment
Thoracic Oncology
The investigator has expertise in treating advanced non-small cell lung cancer (NSCLC), specifically focusing on cases with EGFR mutations. Their work involves evaluating novel treatment strategies for patients who have progressed after initial targeted therapy.
- EGFR-mutated lung cancer
- Targeted therapy resistance
- Combination treatment approaches
Genitourinary Oncology
The investigator conducts research in metastatic prostate cancer, with specific interest in treating patients with homologous recombination repair (HRR) gene mutations. Their work focuses on developing therapeutic strategies for castration-sensitive disease.
- Precision oncology in prostate cancer
- HRR mutation-targeted treatments
- Novel hormone therapy combinations
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.